Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 01, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Bosutinib Tablets, 100 mg and 500 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 01, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Bosutinib Tablets, 100 mg and 500 mg.".